Persistent Systems Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Bajaj Healthcare Limited has informed the Exchange about General Updates- Receipt of Hon ble NCLT Order approving Acquisition of Genrx Pharmaceuticals Private Limited on a Going Concern Basis

MphasiS Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

SPR Auto Technologies Limited has informed the Exchange regarding ''Statement containing details of the ISINs of the Company s Non-Convertible Debentures issued on a private placement basis and outstanding as at September 30, 2026

Raymond Realty Limited has informed the Exchange about Clarifications with regards to queries raised by NSE in the Notice of Extra-Ordinary General Meeting of the Company held on October 08, 2026 for approval of increase in authorized share capital and preferential issue of securities on private placement basis.

Ujjivan Small Finance Bank Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/10/2026 ,inter alia, to consider and approve Update on board meeting - Intimation regarding issue of equity shares on preferential basis

The Press Release titled ''Persistent Opens Third Hyderabad Facility to Strengthen AI and Modernization Delivery'', is as enclosed.

Persistent Systems Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Persistent Opens Third Hyderabad Facility to Strengthen AI and Modernization Delivery ".

The Company has informed the stock exchange regarding receipt of In-Principle approval for issue of shares on preferential basis.

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund

L&T Finance Limited has informed the Exchange regarding allotment of Non Convertible Debentures on a private placement basis.

Please find enclosed the intimation regarding allotment of Non-Convertible Debentures on a Private placement basis

Further to disclosure by PTC India Limited, the holding company of the Company on 19th May 2026 to the stock exchanges, regarding its decision to re-initiate the process of exploring opportunities for monetization of its investment in the Company, subject to necessary approvals, as may be required, appointed Shri Govinda Garg, AVP-CS or any other Officer(s) nominated by MD&CEO (Addl. Charge) as the Nodal Officer for providing timely information/ documents, etc., besides assistance and coordination with PTC India Limited and Advisor(s) appointed by PTC India Limited.

Intimation of the In-Principle Approval Letter received from BSE Limited for issue of 10,00,000 Warrants convertible into 10,00,000 equity shares to the Promoter and Non-Promoter of the Company on an Preferential Basis.

Please find enclosed herewith the certificate under regulation 74(5) of SEBI ( Depositories and Participants) Regulation 2018 for the Quarter ended 30 September, 2026

Asian Petroproducts & Exports Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2026 ,inter alia, to consider and approve 1. Issue of Equity shares on preferential basis to promoter and to Promoter Group pursuant to conversion of unsecured loan. 2. Issue of convertible warrants on preferential basis for cash consideration to promoter and to Promoter Group. 3. Issue of Equity shares on preferential basis for cash consideration to non-Promoter public category. 4. To convene an Extraordinary General Meeting process to seek approval of the Shareholders in respect of the aforesaid, as required. You are requested to kindly take the same on record.

Nazara Technologies Limited informs the Exchange regarding allotment of 2,38,81,711 Equity Shares by way of Preferential issue on private placement basis at its meeting held on October 12, 2026.

Nazara Technologies Limited informs the Exchange regarding allotment of 2,38,81,711 Equity Shares by way of Preferential issue on private placement basis at its meeting held on October 12, 2026.

The Company received In-Principal approval dated 12th October 2026 on Preferential basis of 3871854 equity shares.

SIS Limited has informed the Exchange regarding daily report with respect to Equity Shares bought back by the Company on October 12, 2026.

Non-applicability of Regulation 27(2) as per Regulation 15 of Chapter IV of SEBI (LODR) Regulations, 2015 for the Quarter ended 30th September, 2026

Investor Grievance Redressal Report as per Regulation 13 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC.

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".

Armee Infotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2026 ,inter alia, to consider and approve We would like to inform you that pursuant to Regulation 29 (1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior intimation is hereby given with respect to the meeting of the Board of Directors of Armee Infotech Limited ('the Company'), scheduled to be held on Thursday, 15th October 2026, inter-alia, a. To consider and approve, inter alia, the Unaudited Financial Results (both Standalone and Consolidated) of the Company along with the Limited Review Report of the Statutory Auditors, for the quarter ended June 30, 2026 ('Financial Results'). b. To consider the proposal for the raising of funds by issuance of secured, listed Non-Convertible Debentures on private placement basis, in one or more tranches, and matters incidental thereto. As closure of trading window intimation has been shared with your good office for the quarter ended September 2026. Pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Company's Code of Conduct

Unifinz Capital India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2026 ,inter alia, to consider and approve To consider and if thought fit, approve the proposal of raising of fund by way of issuance of Equity shares/Share Warrants and/or any other eligible securities on a preferential basis, to one or more persons, in accordance with the Companies Act, 2013 read with the rules notified thereunder, each as amended, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and such other acts, rules and regulations, as may be applicable, subject to the approval of the shareholders of the Company and such regulatory /statutory approvals as may be required.

pursuant to the provisions of Regulation 30 read with Schedule III of the SEBI (LoDR) Regulations 2015, we wish to inform you that Unit 1 has resumed its work on a trial basis from the evening of October 11, 2026.

Manba Finance Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve Manba Finance Limited had informed that the Board Meeting is scheduled to be held on October 27, 2026 ,inter alia, to consider and approve, i. the Unaudited Financial Results (Standalone) of the Company for the quarter ended September 30, 2026, ii. declaration of second interim dividend for FY2026-27. At the said meeting the Board shall further consider the fixing of Record date for the second interim dividend, and approval of the fresh issuance upto Rs. 200 crore on private placement basis.

Jubilant Pharmova Limited has informed the Exchange about Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis

Issue of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures on Private Placement Basis

Jubilant Pharmova Limited has informed the Exchange regarding Outcome of Board Meeting held on October 12, 2026 for the Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis

Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis

Allotment of 3,25,18,900 Convertible Warrants on Preferential Basis.

Allotment of 3,25,18,900 Convertible Warrants on Preferential Basis. For more details, please refer attachment.

MphasiS Limited has informed the Exchange regarding Grant of 107578 Options.

Grant of 64434 Employees Stock Options and 43144 Restricted Stock Units

Board meeting held today to consider and approval of issue of shares on preferential basis.

Listing approval for shares allotted on a preferential basis to promoters and non-promoters.

Intimation of receipt of Trading Approval